Laboratory Communications
11/11/2022- Service
update: Resumption of testing for folate, urinary albumin
Reagent stocks are now replenished for both our folate and urinary albumin
(microalbumin) tests and service is now running as normal. Folate requests were
being sent to a third party lab and were continuously processed throughout the
reagent shortage. For microalbumin samples, these were stored frozen and we
have now cleared the backlog, and all results are now available. There were a
very small number where samples were not saved or otherwise lost and reports
issued to this effect. Turn-around times should now be back to those seen prior
to the issues with non-availability of reagent. We apologise for the
inconvenience this may have caused.
11/11/2022- Service
update: ACCP test
Reagent unavailability means that we are presently unable to analyse samples
for anti-cyclic citrullinated peptide antibodies (ACCP). We anticipate that
reagents will once again be available within the coming week. However, this
does mean there will be longer than expected turn-around times in the interim.
We apologise for any inconvenience this may cause.
28/09/2022- Critical
reagent shortage: urinary albumin
Dear colleagues,
Due to circumstances
beyond our control, we are temporarily unable to analyse samples for urinary
albumin (microalbumin). We expect that further reagent will be available in
early October. Please note that samples will be stored frozen and there will be
delays in turn-around time for this assay with the assurance that results will
be available once reagent supply is restored.
Where possible, we advise
that urine sample collection for albumin analysis should be delayed until
reagent supply is restored.
We apologise for the
inconvenience. If you wish to discuss this or any other issue related to lab
service, please contact the Duty Biochemist.
26/09/2022- Critical reagent shortage – Lithium
Due to a critical reagent
issue beyond our control, lithium analysis is not available at Barnsley or
Rotherham laboratories. With immediate effect, all requests for serum lithium
will be sent to an external laboratory (Sheffield Teaching Hospital). The
therapeutic/reference range is unchanged, however users may see an increased
turn-around time. If
there is any clinical suspicion of toxicity and an urgent result is required,
please contact the laboratory to arrange rapid sample processing.
Please accept our apologies for any inconvenience this may cause.
For further information
or discussion, please contact the Duty Biochemist or contact
iain.woodrow@nhs.net or via extension 5749 (01226 435749 if external).
05/09/2022- Critical
reagent shortage- Carbamazepine
Our reagent suppliers have informed us that there is a critical
national shortage of reagents for our carbamazepine assay. We are making
contingency plans to allow us to continue to provide this test, likely
involving sending requests to a third-party laboratory.
However, this is likely to have some impact on
current turn-around times for this assay.
Consequently,
can we please ask that, in the interim, requests for this drug are only sent
when clinically indicated (most notably when there is a suspicion of toxicity
or non-adherence), and not for routine monitoring purposes.
Current estimates from
our reagent manufacturer is that stock
may be restored in early November.
If you would like further
information or wish to discuss this assay or anything else, please do not
hesitate to contact Dr Iain Woodrow iain.woodrow@nhs.net 01226 435749 or the
laboratory at Barnsley or Rotherham
24/08/2022- UPDATE- Critical Folate reagent shortage now until
late-October: please only request if clinically indicated
Due to a further acute
national reagent shortage, we would ask that users please only measure folate where there
is an acute clinical need. Please also consider whether
any test requests for folate could be delayed until reagent supply is restored
(currently anticipated in mid-late October).
We
are likely to completely exhaust our reagent stock and resort to testing at an
laboratory from early September onwards. We plan to send folate requests to
Sheffield Teaching Hospitals Laboratory in this event.
Please note that
turn-around times for folate results may be longer as the test may need to be
performed in batches to conserve reagent. Turnaround times are likely to exceed
24 hours once samples are being sent to Sheffield for analysis. We apologise
for any inconvenience this may cause.
As an aid, see below a
summary of the indications of where haematinic requesting may be indicated.
Please note this is not exhaustive and for guidance only.
Indications
for haematinics requesting:
Suggested indications
for B12 + folate:
|
Suggested indications
for B12 + folate + ferritin:
|
1. Macrocytic anaemia
2. Peripheral neuropathy
3. Oral ulceration
4. Unexplained cerebral decline
5. Anaemia and hypothyroidism
6. Anaemia and thrombocytopenia or
neutropenia
|
1. Unexplained normochromic
normocytic anaemia
2. malabsorption
3. Anaemia and poor diet
|
Please contact the
laboratory if you have any further questions.
30/05/2022-
Critical Folate reagent shortage until mid-July: please only request if
clinically indicated
Due to an acute national
reagent shortage, we ask that clinicians please only measure folate where
there is an acute clinical need. Please also consider whether any test
requests for folate could be delayed until reagent supply is restored
(currently anticipated in mid-July).
We are
likely to completely exhaust our reagent supply and require external testing
from mid-June onwards. We plan to send folate
requests to Sheffield Teaching Hospitals Laboratory in this event.
Please note that turn-around
times for folate results may be longer as the test may need to be performed in
batches to conserve reagent. Turnaround times are likely to exceed 24 hours
once samples are being sent to Sheffield for analysis. We apologise for any
inconvenience this may cause.
As an aid, see below a summary
of the indications of where haematinic requesting may be indicated. Please note
this is not exhaustive and for guidance only.
Indications
for haematinics requesting:
Suggested
indications for B12 + Folate:
1.
Macrocytic anaemia
2.
Peripheral neuropathy
3.
Oral ulceration
4.
Unexplained cerebral decline
5.
Anaemia and hypothyroidism
6.
Anaemia and thrombocytopenia or neutropenia
Suggested
indications for B12 + folate + ferritin:
1.
Unexplained normochromic normocytic anaemia
2.
?malabsorption
3.
Anaemia and poor diet
Please contact the laboratory
if you have any further questions.
10/05/2022 – Cortisol assay: cross-reactivity with Prednisolone
Please be reminded that there is significant cross-reactivity in our cortisol assay with many synthetic glucocorticoids, particularly prednisolone. Please be aware that when undertaking any investigations involving measuring cortisol in patients on prednisolone (including dynamic function tests), the measured result will have a significant positive bias and be unlikely to reflect the concentration of the native hormone. Please contact the lab for further advice or discussion
01/04/2022- Critical FT4 reagent shortage: change to test availability and turn-around times
Due to an acute national reagent shortage, FT4 will only be measured on samples with an abnormal TSH from Monday 4 April. FT4 will not be available to request directly from ICE, Meditech or via paper requests, but will be automatically added in the laboratory to samples with an abnormal TSH result.
If there is a strong clinical need for FT4 analysis on your patient, please contact the biochemistry laboratory directly.
Please note that turn-around times for FT4 results will be longer as the test will only be performed at Barnsley laboratory (as of 31.03.22), with weekend samples being batched for one analytical run on Sunday, except for clinically urgent requests
This is a temporary measure and we hope to resume our normal procedure as soon as reagent stocks are back to normal. We apologise for any inconvenience this may cause.
14/12/2021-
Digoxin Changes
From 20/12/21 we will be
updating our quoted
therapeutic range for digoxin to: 0.7 – 2.0 ug/L.
This revised therapeutic range
brings us in line with the NICE Clinical Guideline for Atrial Fibrillation (https://cks.nice.org.uk/topics/atrial-fibrillation/prescribing-information/digoxin/).
There will be an accompanying
text comment regarding digoxin concentration in patients with heart failure to
reflect the narrower therapeutic window in heart failure:
“Therapeutic target of 0.5-1.0
ug/L in heart failure.”
For patients being treated for
digoxin toxicity, please note that
Digifab interferes with digoxin immunoassays, so there is no clinical
benefit in checking digoxin levels after Digifab administration.
14/12/2021-
Microbiology
Antimicrobial susceptibility interpretation guidance
As
from the 11/1/22, the Microbiology department will be reporting antimicrobial
susceptibility results as per the updated guidance released by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST). The new
interpretations are categorised and defined into three susceptibility
categories:
- S - Susceptible, standard
dosing regimen: A microorganism is
categorised as Susceptible, standard dosing regimen, when there is a high
likelihood of therapeutic success using a standard dosing regimen of the
agent.
- I (High dose)
- Susceptible, increased exposure:
A microorganism is categorised as Susceptible, increased exposure* when
there is a high likelihood of therapeutic success because exposure to the
agent is increased by adjusting the dosing regimen or by its concentration
at the site of infection.
- R - Resistant:
A microorganism is categorised as Resistant when there is a high
likelihood of therapeutic failure even when there is increased exposure.
*Exposure is a function of how the
mode of administration, dose, dosing interval, infusion time, as well as
distribution and excretion of the antimicrobial agent will influence the
infecting organism at the site of infection
Please
refer to the antimicrobial policy for further information. Alternatively,
contact the microbiology department or senior clinical pharmacist if further
guidance is required.
29/11/2021-
Communication: eGFR and KFRE
In August
2021 NICE published an updated “Chronic kidney disease: assessment and
management” guideline (NG203). This includes two new considerations for users
of Blood Sciences at BRILS who request tests of renal function:
1)
Removing adjustment for ethnicity from eGFR
The
guidance to adjust for ethnicity when calculating the estimated glomerular
filtration rate (eGFR) in people from Afro-Caribbean ethnic groups is no longer
deemed to be valid.
The NICE
Committee agreed that adding an ethnicity adjustment to eGFR equations for
different ethnicities is not supported by evidence from available studies, and,
because the muscle mass varies widely between individuals within the same
ethnicity, the adjustment may not be accurate for all individuals within any
given ethnic group
In
addition, NICE reiterated that eGFR creatinine may be less reliable in certain
situations such as acute kidney injury; pregnancy; oedematous states; muscle
wasting disorders; in those who are malnourished, have higher muscle mass, use
protein supplements or those who have undergone amputation. (Please note
that although not specifically mentioned in NICE guidance, sports supplements,
especially those containing creatine may also make eGFR creatinine
interpretation less reliable.)
2) Kidney
Failure Risk Equation (KFRE)
There is
an update related to assessing the risk of patients with known CKD progressing
to require renal replacement therapy.
NICE now
suggest that adults with CKD are provided with a risk score, calculated
using the 4-variable kidney failure risk equation (KFRE). The equation
uses patient age, gender, eGFR and urinary Albumin to Creatinine ratio to
calculate the kidney failure risk. The recommendation is that patients are
referred for specialist assessment, should their 5 year risk from the
calculation be greater than 5%.
The
current version of our laboratory information management system (LIMS) is
unable to calculate this score, but while we are addressing this, we will
provide on ICE and the pathology website a link to the risk calculator on the
NICE website. Please use this calculator where appropriate, according to
guidance.
As a result of these updates, from the 29th of
November the comment appended to eGFR results on lab reports will be as
follows:
“NICE no
longer recommend any correction to eGFR for ethnicity. Please interpret with
caution in patients with extremes of muscle mass, or other confounding factors.
For more info see https://tinyurl.com/4hjbeaac”
There
will also be additional code linked to UEs results with the following comment:
“For KFRE
calculator refer to: https://www.nice.org.uk/guidance/ng203/resources
or a link on ICE.”
23/11/2021- Communication: Sample Transportation Reminder
For
all users of BRILS please note that timely transport of samples to the
laboratory is important in ensuring sample integrity and subsequent patient
results. Can all GP and community users please ensure that samples are
transported on the next available collection. Refrigeration of samples prior to
collection can also affect sample integrity and may lead to spurious results so
please do not store samples in a fridge prior to transport. Please see our user
webpage for further information: https://www.barnsleyhospital.nhs.uk/pathology/pathology-general/transport-spceimens-laboratory/
23/11/2021-
Communication: Reminder- Phlebotomy Outpatients
The
Phlebotomy service is now appointment only and appointments can be booked by
telephoning 01226 433969 between 8:00 and 16:50 Monday to Friday. Please
note that the appointment line is very busy and often patients will have to try
multiple times to get through. We are aware of the difficulties and a
solution is being looked into to improve the appointment system. We apologies
for any inconvenience caused.
21/10/2021- Communication: Changes to
repeat Biochemistry requests for slightly haemolysed samples
BRILS
blood sciences laboratories replaced their automated analysers in Autumn 2020.
As a result of feedback from users about the impact that increased detection of
slightly haemolysed samples is having on repeat biochemistry requests,
especially for potassium, we are changing the haemolysis level at which a
repeat sample is advised for certain tests. This will not have any impact on
the clinical validity of results.
From
1st November 2021, you should see fewer repeat requests in slightly haemolysed
samples for the following biochemistry tests:
• Potassium
• BNP
• Creatine Kinase (CK)
• Uric acid (urate)
Please
contact Cat Dibden if you have any queries about
this change.
Published on Wednesday 30 May 2022 by Jayshree Sisodia